Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Hepatocellular Carcinoma (HCC)
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
The main objective of the trial is to document the progression free survival (PFS) in
advanced or metastatic hepatocellular carcinoma patients treated with NGR-hTNF as single
agent.
Safety will be established by clinical and laboratory assessment according to NCI-CTC
criteria